• Publications
  • Influence
Chlamydia pneumoniae (TWAR).
TLDR
The microimmunofluorescence serologic assay is specific for TWAR and can distinguish between recent and past infections, and PCR techniques have recently facilitated its detection in tissues and clinical specimens. Expand
A NEW RESPIRATORY TRACT PATHOGEN: CHLAMYDIA PNEUMONIAE STRAIN TWAR
  • J. Grayston
  • Biology, Medicine
  • The Journal of infectious diseases
  • 1 April 1990
Chlamydia pneumoniae strain TWAR, the new third species of Chlamydia, is a common cause of pneumonia and other acute respiratory tract infections. About 10% of hospitalized and outpatient pneumoniaExpand
New and Emerging Etiologies for Community‐Acquired Pneumonia with Implications for Therapy: A Prospective Multicenter Study of 359 Cases
TLDR
There were no distinctive clinical features found to be diagnostic for any etiologic agent, although high fever occurred more frequently in Legionnaires' disease, and realization that C. pneumoniae and Legionella spp. Expand
Immunologic relationship between genital TRIC, lymphogranuloma venereum, and related organisms in a new microtiter indirect immunofluorescence test.
TLDR
Terminology for the morphologically simiilar psittacosis, lymphogranuloma venereum (LGV), trachoma organisms has been fused and terminology and tentatively grouped TRIC organisms and other species C. tra­ chomatis strains are developed. Expand
A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections.
TLDR
Clinically, the infections resembled those with Myco-plasma pneumoniae; therefore, the patients were given courses of erythromycin used for the treatment of M. pneumoniae infections, and this therapy proved to be inadequate. Expand
Azithromycin for the secondary prevention of coronary events.
TLDR
A one-year course of weekly azithromycin did not alter the risk of cardiac events among patients with stable coronary artery disease and there were no significant risk reductions with regard to the components of the primary end point, death from any cause, or stroke. Expand
Immunotyping of Chlamydia trachomatis with monoclonal antibodies.
Rapid and precise immunotyping of Chlamydia trachomatis was achieved by testing whole organisms (elementary bodies) in the microimmunofluorescence test with monoclonal antibodies. MonoclonalExpand
Background and current knowledge of Chlamydia pneumoniae and atherosclerosis.
  • J. Grayston
  • Biology, Medicine
  • The Journal of infectious diseases
  • 1 June 2000
TLDR
Attributes of Chlamydia pneumoniae of potential importance to a relationship with Atherosclerosis are described and the conclusive demonstration of an association of C. pneumoniae and atherosclerosis by the repeated and frequent finding of the organism in atherosclerotic tissue is demonstrated. Expand
Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery.
TLDR
Findings do not establish causality for C pneumoniae in carotid artery atherosclerosis, but they should stimulate investigation of a possible causal or pathogenic role for the organism in the disease. Expand
Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain.
TLDR
A wider involvement of C pneumoniae organisms in atherosclerotic lesions of the arterial system than has previously been documented is suggested. Expand
...
1
2
3
4
5
...